RT Journal
A1 Leibowitz HM, Bartlett JD, Rich R, McQuirter H, Stewart R, Assil K
T1 INtraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids
JF Archives of Ophthalmology
JO Archives of Ophthalmology
YR 1996
FD August 1
VO 114
IS 8
SP 933
OP 937
DO 10.1001/archopht.1996.01100140141005
UL http://dx.doi.org/10.1001/archopht.1996.01100140141005
AB Objective: 
    To compare the intraocular pressure (IOP) elevating potential of 1.0% rimexolone and 0.1% fluorometholone alcohol ophthalmic suspensions in patients known to have responded to corticosteroids.Design: 
    In a double-masked, randomized, single-eye, crossover protocol, corticosteroid responsiveness initially was verified in 40 asymptomatic known steroid responders by challenge with either 0.1% dexamethasone sodium phosphate or 1.0% prednisolone acetate for up to 6 weeks. After a 1-month medication washout, subjects randomly received either rimexolone or fluorometholone for 6 weeks. Medications were again discontinued for 1 month, and subjects then received the alternate drug for 6 weeks.Results: 
    There was no significant difference between rimexolone and fluorometholone in the number of subjects demonstrating a 10-mm Hg increase in IOP or in the mean number of weeks required to achieve a 10-mm Hg response. Responses occurred in significantly more subjects receiving dexamethasone sodium phosphate (P=.001) or prednisolone acetate (P<.001) and in a significantly shorter interval than in subjects receiving rimexolone.Conclusions: 
    Rimexolone has a low IOP-elevating potential, comparable to that of fluorometholone and less than that of dexamethasone sodium phosphate and prednisolone acetate.